IL6 and metabolic dysfunction-associated steatohepatitis: Moreover, in a preclinical rat model with NASH [44], sorafenib was able to reduce collagen, increase matrix metalloproteinase (MMP) mRNA levels, and decrease the protein expression of tissue metallopeptidase inhibitor-1 (TIMP-1) as well as the pro-inflammatory interleukins (IL)-6 and 10 [44].